SAB Biotherapeutics, Inc. Income Statement

Income Statement Dec2020 Dec2021 Dec2022 Dec2023 Dec2024
Revenue & cost
Revenue 55.24M60.88M23.90M2.24M1.32M
Gross Profit 55.24M60.88M23.90M2.24M1.32M
Operating items
Research & Development 27.91M57.18M36.44M16.52M30.25M
Selling, General & Administrative 6.77M17.09M16.38M23.80M13.98M
Operating Expenses 34.68M74.27M52.82M40.31M44.23M
Operating Income 20.56M-13.39M-28.92M-38.08M-42.91M
EBIT 20.56M-13.39M-28.92M-38.08M-42.91M
Non-operating items
Interest & Investment Income 0.03M0.02M0.07M0.58M1.29M
Other Non Operating Income 0.00M0.67M0.03M0.44M2.45M
Non Operating Income 0.00M0.01M10.20M-4.12M8.81M
Net income details
EBT 20.11M-17.14M-18.72M-42.19M-41.94M
Tax Provisions 0.03M
Profit After Tax 20.12M-17.14M-18.74M-42.19M-34.11M
Income from Continuing Operations 20.11M-17.14M-18.74M-42.19M-41.94M
Consolidated Net Income 20.11M-17.14M-18.74M-42.19M-41.94M
Income towards Parent Company 20.11M-17.14M-18.74M-42.19M-41.94M
Net Income towards Common Stockholders 20.12M-17.14M-18.74M-42.19M-34.11M
Additional items
EPS (Basic) 0.00M-0.00M-0.00M-0.00M-0.00M
EPS (Weighted Average and Diluted) 0.00M-0.00M-0.00M-0.00M-0.00M
Shares Outstanding (Weighted Average) 4.39M4.35M4.30M5.23M9.23M
Shares Outstanding (Diluted Average) 4.35M5.52M9.26M
EBITDA 20.56M-13.39M-28.92M-38.08M-42.91M
Shares Outstanding 25.97M4.35M5.09M9.28M9.34M